On The Radar – 7th Edition
By
The article argues that focusing solely on drugmakers oversimplifies the U.S. pricing crisis. Wholesalers, pharmacies, and PBMs all play roles in driving up costs, particularly through opaque rebate systems that often fail to benefit consumers.
➡ Why it matters: True reform will require addressing every layer of the supply chain, not just manufacturers.
Analysts question whether new direct-to-consumer (DTC) discount platforms like TrumpRx will meaningfully lower costs, calling them “performative.” The Inflation Reduction Act (IRA) remains the most impactful federal reform to date, with negotiated drug prices and new out-of-pocket caps for seniors.
➡ Why it matters: The politics of pricing are heating up, and employers should watch how competing federal policies shape pharmacy costs.
The FDA is launching a pilot program to accelerate approval for generics made entirely in the U.S., aiming to reduce reliance on foreign production and strengthen national security.
➡ Why it matters: Increased domestic production could stabilize the supply chain and reduce vulnerability to global disruptions.
Researchers at the University of Maine discovered a way to produce key drug ingredients from plant-based materials instead of petrochemicals, cutting costs by over 60 percent while reducing carbon emissions.
➡ Why it matters: Innovations like this could lower prices and improve sustainability across the pharmaceutical industry.
New state laws are restricting plan control over specialty drug sites of service and prior authorizations, forcing plans to find new ways to manage expenses. Strategies include patient education, site-neutral payments, and collaboration with providers.
➡ Why it matters: Balancing cost management and patient access will be a key challenge as PBM oversight increases.
Following the introduction of Stelara biosimilars, PBMs plan to exclude Johnson & Johnson’s reference drug in favor of their own private-label versions. The move could accelerate savings but limit market competition.
➡ Why it matters: Employers may see short-term price relief but should remain cautious about PBM-driven market consolidation.
The orphan biomarkers market is projected to triple by 2035, driven by increased investment in precision medicine and rare disease diagnostics, especially in North America.
➡ Why it matters: Expanding research in orphan diseases creates opportunities for better treatments but raises long-term affordability questions.
The administration continues to pursue Most Favored Nation (MFN) pricing while developing new payment models under review by the Office of Management and Budget. At the state level, Colorado set the nation’s first upper payment limit under its PDAB program.
➡ Why it matters: Coordination between state and federal reforms is reshaping how drug prices are negotiated and capped.
Facing bipartisan pressure, PBMs are proposing voluntary reforms like limiting out-of-pocket costs and supporting rural pharmacies to preempt government regulation.
➡ Why it matters: Self-regulation may delay, but not replace, the push for binding federal PBM oversight.
With PBMs now controlling 80 percent of prescription claims, regulators and states are cracking down on opaque pricing and rebate systems. The FTC lawsuit against the Big 3 PBMs marks a new era of scrutiny.
➡ Why it matters: Transparency and data access are becoming essential as employers and plan sponsors face increasing fiduciary accountability.
Final Thoughts
From new manufacturing pilots to DTC platforms and sweeping PBM reform, the U.S. healthcare market is transforming at every level. Employers and brokers must keep pace by demanding transparency, evaluating vendor practices, and leveraging innovation to protect both plan budgets and member health.
We’ll be back in two weeks with more news you need to know. If you’d like a custom analysis or want to explore SHARx program options for your clients, contact us!
Stay Connected with SHARx
Subscribe to our newsletter for monthly updates from our CEO, curated industry news, insights from our in-house pharmacist, the latest blog posts, and more. Just fill out the form to stay informed.
Newsletter Sign-up
Be the first to learn what’s new with SHARx.